JP2014507445A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507445A5
JP2014507445A5 JP2013555599A JP2013555599A JP2014507445A5 JP 2014507445 A5 JP2014507445 A5 JP 2014507445A5 JP 2013555599 A JP2013555599 A JP 2013555599A JP 2013555599 A JP2013555599 A JP 2013555599A JP 2014507445 A5 JP2014507445 A5 JP 2014507445A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
aryl
heteroaryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507445A (ja
JP6043733B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/026517 external-priority patent/WO2012116279A1/en
Publication of JP2014507445A publication Critical patent/JP2014507445A/ja
Publication of JP2014507445A5 publication Critical patent/JP2014507445A5/ja
Application granted granted Critical
Publication of JP6043733B2 publication Critical patent/JP6043733B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555599A 2011-02-25 2012-02-24 カンナビノイド受容体モジュレーター Expired - Fee Related JP6043733B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446729P 2011-02-25 2011-02-25
US61/446,729 2011-02-25
PCT/US2012/026517 WO2012116279A1 (en) 2011-02-25 2012-02-24 Cannabinoid receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016221615A Division JP2017039773A (ja) 2011-02-25 2016-11-14 カンナビノイド受容体モジュレーター

Publications (3)

Publication Number Publication Date
JP2014507445A JP2014507445A (ja) 2014-03-27
JP2014507445A5 true JP2014507445A5 (cg-RX-API-DMAC7.html) 2015-04-09
JP6043733B2 JP6043733B2 (ja) 2016-12-14

Family

ID=46000314

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013555599A Expired - Fee Related JP6043733B2 (ja) 2011-02-25 2012-02-24 カンナビノイド受容体モジュレーター
JP2016221615A Withdrawn JP2017039773A (ja) 2011-02-25 2016-11-14 カンナビノイド受容体モジュレーター
JP2018106019A Withdrawn JP2018162260A (ja) 2011-02-25 2018-06-01 カンナビノイド受容体モジュレーター
JP2020028389A Withdrawn JP2020079302A (ja) 2011-02-25 2020-02-21 カンナビノイド受容体モジュレーター
JP2022029449A Pending JP2022066289A (ja) 2011-02-25 2022-02-28 カンナビノイド受容体モジュレーター

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016221615A Withdrawn JP2017039773A (ja) 2011-02-25 2016-11-14 カンナビノイド受容体モジュレーター
JP2018106019A Withdrawn JP2018162260A (ja) 2011-02-25 2018-06-01 カンナビノイド受容体モジュレーター
JP2020028389A Withdrawn JP2020079302A (ja) 2011-02-25 2020-02-21 カンナビノイド受容体モジュレーター
JP2022029449A Pending JP2022066289A (ja) 2011-02-25 2022-02-28 カンナビノイド受容体モジュレーター

Country Status (11)

Country Link
US (6) US20140206649A1 (cg-RX-API-DMAC7.html)
EP (2) EP2678318A1 (cg-RX-API-DMAC7.html)
JP (5) JP6043733B2 (cg-RX-API-DMAC7.html)
CN (2) CN103492369B (cg-RX-API-DMAC7.html)
AU (1) AU2012222149B2 (cg-RX-API-DMAC7.html)
DK (1) DK3385252T3 (cg-RX-API-DMAC7.html)
ES (1) ES2929977T3 (cg-RX-API-DMAC7.html)
IL (2) IL227779A0 (cg-RX-API-DMAC7.html)
MX (2) MX346644B (cg-RX-API-DMAC7.html)
PT (1) PT3385252T (cg-RX-API-DMAC7.html)
WO (1) WO2012116279A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201901293RA (en) * 2009-08-28 2019-03-28 Arena Pharm Inc Cannabinoid receptor modulators
ES2929977T3 (es) 2011-02-25 2022-12-05 Arena Pharm Inc Moduladores del receptor cannabinoide
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
BR112013021549B1 (pt) 2011-02-25 2022-01-11 Arena Pharmaceuticals, Inc Processos para preparação de forma cristalina anidra, para preparação de composição farmacêutica e para preparação de forma de dosagem, forma cristalina não solvatada anidra, composição farmacêutica, forma de dosagem, uso da referida forma cristalina e solvato
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
BR112018070786A2 (pt) * 2016-04-10 2019-02-05 Arena Pharm Inc métodos de tratamento com agonistas do receptor de cb2 seletivos
JP7247106B2 (ja) 2017-05-08 2023-03-28 アリーナ ファーマシューティカルズ， インコーポレイテッド 内臓痛の治療のための化合物および方法
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TWI768464B (zh) * 2019-09-12 2022-06-21 大陸商四川海思科製藥有限公司 三環吡唑衍生物及其製備
CN118843120A (zh) * 2020-09-07 2024-10-25 中兴通讯股份有限公司 资源确定方法、通信节点及存储介质
US20250129090A1 (en) 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
EP4514808B1 (en) 2022-04-27 2025-12-17 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
EP4522624A1 (en) 2022-05-12 2025-03-19 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US236010A (en) 1880-12-28 Wilhelm effer
US5605906A (en) 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US7308894B2 (en) 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
ATE368037T1 (de) 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
US20040259936A1 (en) 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
IL150302A (en) 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
MX2007000491A (es) 2004-07-12 2007-03-28 Cadila Healthcare Ltd Nuevos compuestos heterociclicos.
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) * 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2613678A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7597910B2 (en) 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
CN101312952B (zh) * 2005-09-23 2012-12-26 詹森药业有限公司 四氢-环戊二烯并吡唑大麻素调节剂
EA200970080A1 (ru) 2006-07-04 2009-06-30 Янссен Фармацевтика Нв Бензимидазольные агонисты каннабиноидов, содержащие замещенную гетероциклическую группу
JP5030114B2 (ja) 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
RU2009117203A (ru) 2006-11-03 2010-12-10 Гленмарк Фармасеутикалс С.А. (Ch) Новые лиганды каннабиноидных рецепторов, фармацевтические композиции, содержащие данные лиганды, и способы их получения
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
WO2008079316A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
JP5504153B2 (ja) 2007-03-30 2014-05-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾールカンナビノイドアゴニスト
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
AU2008265655B2 (en) 2007-06-21 2014-02-06 Cara Therapeutics, Inc. Substituted imidazoheterocycles
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US20120004222A1 (en) 2007-08-21 2012-01-05 Zhicai Wu Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010088050A2 (en) * 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
SG10201901293RA (en) * 2009-08-28 2019-03-28 Arena Pharm Inc Cannabinoid receptor modulators
ES2929977T3 (es) 2011-02-25 2022-12-05 Arena Pharm Inc Moduladores del receptor cannabinoide
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
BR112013021549B1 (pt) 2011-02-25 2022-01-11 Arena Pharmaceuticals, Inc Processos para preparação de forma cristalina anidra, para preparação de composição farmacêutica e para preparação de forma de dosagem, forma cristalina não solvatada anidra, composição farmacêutica, forma de dosagem, uso da referida forma cristalina e solvato

Similar Documents

Publication Publication Date Title
JP2014507445A5 (cg-RX-API-DMAC7.html)
KR101677126B1 (ko) 탄산염 프로드러그 및 그것의 사용 방법
JP5598775B2 (ja) 癌の介入治療および根絶のためのｉｔｅとその類似体を含む医薬組成物
JP2011520977A5 (cg-RX-API-DMAC7.html)
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
US20100209459A1 (en) Alkaloid formulations
CA2544648C (en) Analgesic compounds, their synthesis and pharmaceutical compositions containing them
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
JP2018162260A (ja) カンナビノイド受容体モジュレーター
JP2018520195A5 (cg-RX-API-DMAC7.html)
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
CN103619330A (zh) 用于治疗糖尿病的选择性雄激素受体调节剂
MA33922B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
JP2016516773A5 (cg-RX-API-DMAC7.html)
AU2012262061A1 (en) Compositions for sequential administration of opioid receptor agonists
JP2012516288A (ja) 薬物乱用抑制剤、方法および組成物
Tunn et al. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases
CN109758452A (zh) 胺类化合物治疗疼痛的医药用途
US20110136885A1 (en) Synergistic Combination of Analgesic Compounds
RU2010140888A (ru) Улучшенные противораковые терапии
JP2011502985A5 (cg-RX-API-DMAC7.html)
JP2013227347A5 (cg-RX-API-DMAC7.html)
CZ2006623A3 (cs) Kombinace deramciklanu a opioidů jako analgetik
WO2015021324A1 (en) Filanesib combined with pomalidomide displays enhanced anti-tumor activity
Tammela et al. Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: analysis of data from the ARADES and the ARAFOR trials